Author:
He Weili,Jung Tae Hyun,Wang Hongwei,Dharmarajan Sai
Publisher
Springer International Publishing
Reference36 articles.
1. About Merkel Cell Skin Cancer. https://www.cancer.org/cancer/merkel-cell-skin-cancer/about.html (2022). Accessed.
2. Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294–301. https://doi.org/10.1002/cam4.815.
3. FDA. Multi-Discipline review of avelumab (BLA 761049). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761049Orig1s000MultidisciplineR.pdf 2017.
4. FDA. Multi-Discipline review of tafasitamab-cxix (BLA 761163). https://www.accessdata. fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf 2020.
5. Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, Liberati AM, De Vos S, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021. https://doi.org/10.3324/haematol.2021.279802.